"ARIUS is very pleased to collaborate with Dr. John Dick, a pioneer in
the cancer stem cell field. Prior to collaborating with Dr. Dick, our CD9
antibody demonstrated potent anti-tumor activity in several pre-clinical
solid tumor models. Our antibody also appears to be a specific cancer stem
cell inhibitor, suggesting that it may become an important drug and forge
new paths for the treatment of cancer," said Dr. Daniel S. Pereira, Vice
President of Research of ARIUS. "We have identified large and small animal
toxicology models suitable for further studies of AR40A746.2.3 and we are
on track in the development of this molecule for human clinical trials."
CD9 is a potential marker of acute myeloid leukemia stem cells (LSC) and
serves as a LSC-specific therapeutic target. Poster Session A, Wednesday,
Feb 13th 2008, from 4:30-6:30 pm in the Concourse Ballroom of the Los
AR40A746.2.3, a functional antibody that targets CD9, has previously been shown to have anti-tumor and survival benefits in animal models of human breast and pancreatic cancer. CD9 is highly expressed and differentially expressed in AML versus normal stem cells (42.7+10.1% verus 9.9+2.8%). Preliminary experiments show that targeting CD9 with AR40A746.2.3 inhibits human AML outgrowth in the NOD/SCID mouse xenotransplant model. In secondary transplantation experiments, treatments with AR40A746.2.3 dramatically reduced the self-renewal capacity of AML cancer stem cells.
ARIUS is a biotechnology company discovering and developing the next
wave of antibody therapeutics. Established in 1999, ARIUS has built a
|SOURCE ARIUS Research Inc.|
Copyright©2008 PR Newswire.
All rights reserved